Sector News

Sanofi aims to save 1,100 jobs in Bangladesh by selling its local stake: report

October 17, 2019
Life sciences

Sanofi has been weighing strategic options in Bangladesh for several weeks, and now it’s decided to leave the country, an executive told reporters.

The drugmaker’s local managing director Muin Uddin Mazumder this week said the company is selling its assets there and plans to exit within 12 to 18 months, the Daily Star reports. The Bangladeshi government owns 45.36% of the company’s local outfit, while Sanofi owns the remaining 54.64% stake.

Sanofi’s not selling out its 1,100 employees in the country, though, Mazumder said. The drugmaker plans to unload its stake only to a buyer that pledges to keep employees on the payroll, he said. Sanofi hasn’t been in touch with any potential buyers, though, he added.

Last month, a Sanofi spokesman told FiercePharma the company was considering strategic options in the country, adding that “as a responsible company, our employees’ interests will always remain our priority.” The decision comes after new Sanofi CEO Paul Hudson took up the reins last month.

Sanofi’s emerging markets sales grew 7.5% last year to more than €10 billion, helping offset declines elsewhere.

Mazumder told reporters it’s a “global decision” to exit the country and doesn’t reflect local performance, the Daily Star reports. The decision comes early into Hudson’s tenure after he joined the French drugmaker from Novartis. So far, he’s been on a “listening tour” of Sanofi sites in various countries, and he’s now developing a strategy to present at an investor event in December.

Aside from the move in Bangladesh, Sanofi recently said it’s cutting jobs in Japan through voluntary early retirements. But it’s also expanding elsewhere by opening a $47 million headquarters in the U.K. and unveiling plans for a new shared services site in Hungary.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.